Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases
- PMID: 7503602
Pneumocystis carinii pneumonia in patients without AIDS, 1980 through 1993. An analysis of 78 cases
Abstract
Background: Pneumocystis carinii pneumonia (PCP) occurs in immunocompromised patients without the acquired immunodeficiency syndrome (AIDS). There has been an increasing yearly number of cases of PCP in our patients without AIDS.
Objective: To determine the nature of the underlying disorder and previous immunosuppressive treatment in patients with PCP without AIDS.
Method: A study of the charts of 78 such patients admitted to our hospital from 1980 through 1993.
Results: The number of PCP cases per year increased during the period studied. All patients had an underlying disorder, either hematologic malignancy (49%), solid organ tumor (4%), vasculitis or other immunologic disorder (22%), or they had undergone renal transplantation (17%) or bone marrow transplantation (9%). Previous immunosuppressive medication consisted of prednisone or other corticosteroids in 72 (92%) of 78 patients, cytotoxic drugs in 55 (71%) of 78 patients, both in 50 (64%) of 78 patients, and none in one patient. Quantification of previous corticosteroid treatment showed a large variability among patients. The overall mortality rate for patients was 35% (27/78). Mortality was significantly higher in patients with a concomitant pulmonary infection (P = .01), an underlying disorder other than that which resulted in renal transplantation (P = .03), mechanical ventilation (P < .001), previous chemotherapy (P = .04), as well as previous cyclophosphamide treatment (P = .01). A trend toward a higher mortality in patients with previous corticosteroid use was detected (P = .06).
Conclusion: Pneumocystis carinii pneumonia may complicate a variety of immunocompromised states, with considerable mortality. Pneumocystis carinii pneumonia occurred at all levels of immunosuppression; no threshold level could be defined.
Similar articles
-
Pneumocystis carinii pneumonia in patients without HIV infection.J Med Assoc Thai. 2003 Jul;86(7):612-6. J Med Assoc Thai. 2003. PMID: 12948254
-
Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients.Eur J Clin Microbiol Infect Dis. 2002 Jul;21(7):523-31. doi: 10.1007/s10096-002-0758-5. Epub 2002 Jul 13. Eur J Clin Microbiol Infect Dis. 2002. PMID: 12172743
-
[Pneumocystis carinii pneumonia in HIV-negative immunosuppressed patients].Schweiz Med Wochenschr. 1992 Jan 18;122(3):45-54. Schweiz Med Wochenschr. 1992. PMID: 1733012 German.
-
Pneumocystis pneumonia: clinical presentation and diagnosis in patients with and without acquired immune deficiency syndrome.Semin Respir Infect. 1998 Dec;13(4):289-95. Semin Respir Infect. 1998. PMID: 9872625 Review.
-
Pneumocystis carinii pneumonia among patients with neoplastic disease.Semin Respir Infect. 1992 Jun;7(2):114-21. Semin Respir Infect. 1992. PMID: 1439321 Review.
Cited by
-
Pneumocystis carinii pneumonia in HIV-negative patients with haematologic disease.Infection. 1997 Mar-Apr;25(2):78-81. doi: 10.1007/BF02113579. Infection. 1997. PMID: 9108180
-
Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide.Clin Cancer Res. 2011 Aug 15;17(16):5473-80. doi: 10.1158/1078-0432.CCR-11-0774. Epub 2011 Jul 7. Clin Cancer Res. 2011. PMID: 21737504 Free PMC article.
-
Prognostic impact of early adjunctive corticosteroid therapy in non-HIV oncology or haematology patients with Pneumocystis jirovecii pneumonia: A propensity score analysis.PLoS One. 2021 Apr 22;16(4):e0250611. doi: 10.1371/journal.pone.0250611. eCollection 2021. PLoS One. 2021. PMID: 33886692 Free PMC article.
-
Human herpes virus co-infection is associated with mortality in HIV-negative patients with Pneumocystis jirovecii pneumonia.Eur J Clin Microbiol Infect Dis. 2013 Feb;32(2):189-94. doi: 10.1007/s10096-012-1730-7. Epub 2012 Aug 22. Eur J Clin Microbiol Infect Dis. 2013. PMID: 22930407 Free PMC article.
-
Immune modulation with sulfasalazine attenuates immunopathogenesis but enhances macrophage-mediated fungal clearance during Pneumocystis pneumonia.PLoS Pathog. 2010 Aug 19;6(8):e1001058. doi: 10.1371/journal.ppat.1001058. PLoS Pathog. 2010. PMID: 20808846 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources